$heff's $tation of $tocks & $olid DD

[$heff]

CHTP..$2.68..Note out today from Roth Capital:

Roth Capital optimistic on Chelsea Therapeutics
The important takeaway from Chelsea Therapeutics' (CHTP -2.9%) Q2 report is that the re-filing for Northera remains on track for this month, Roth Capital says, maintaining a Buy rating and a $4 price target.
Late last month the FDA identified certain "technical deficiencies" in the NDA for Northera.
There are "no surprises in the 10-Q," and "the risk/reward" is favorable for "risk-tolerant investors," Roth adds.